FDG PET/CT response evaluation in malignant pleural mesothelioma pa-tients treated with talc pleurodesis and chemotherapy

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 241-245

  Genestreti, Giovenzio ^a   Moretti, Andrea ^b   Piciucchi, Sara ^b   Giovannini, Noemi ^a   Galassi, Riccardo ^b   Scarpi, Emanuela ^a   Burgio, Marco Angelo ^a   Amadori, Dino ^a   Sanna, Stefano ^b   Poletti, Venerino ^b   Matteucci, Federica ^b   Gavelli, Giampaolo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

18F FDG PET CT scan; Fluorodeoxyglucose; Malignant pleural mesothelioma; SUV; Talc pleurodesis

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; PEMETREXED; TALC;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MALE; PLEURA MESOTHELIOMA; PLEURODESIS;

EID: 84880572409     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2586     Document Type: Article

References (27)

1. Bethune N. Pleural poudrage: a new technique for the deliberate production of pleural adhesions as a preliminary to lobectomy. J Thorac Surg. 1935;4:251-61.
2. Weissberg D. Talc pleurodesis: a matter of priority. AJR Am J Roentgenol. 1997;169:911.
3. Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg. 1993;106:689-95.
4. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneu-mothorax and pleural effusion. Chest. 1994;106:1215-22.
5. Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J. 1997;10:1648-54.
6. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-9.
7. Murray JG, Erasmus JJ, Bahtiarian EA, Goodman PC. Talc pleu-rodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:359-60.
8. Ahmadzadehfar H, Palmedo H, Strunk H, Biersack HJ, Habibi E, Ezziddin S. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer. 2007;58:418-21.
9. Al-Sarraf N, Doddakula K, Wedde T, Young V. Positron emission tomography staging of pleural deposits following Monaldi's pro-cedure: an accurate reflection or a false staging? Interact Cardiovasc Thorac Surg. 2007;6:260-1.
10. Peek H, van der Bruggen W, Limonard G. Pleural FDG Uptake More Than a Decade after Talc Pleurodesis. Case Report Med. 2009;2009:650864.
11. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax. 1997;52:187-9.
12. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175:245-9.
13. Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918-24.
14. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest. 2004;125:2356-60.
15. Weiss N, Solomon SB. Talc pleurodesis mimics pleural metastases: differentiation with positron emission tomography/computed to-mography. Clin Nucl Med. 2003;28:811-4.
16. Nguyen NC, Tran I, Hueser CN, Oliver D, Farghaly HR, Osman MM. F-18 FDG PET/CT characterization of talc pleu-rodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med. 2009;34:886-90.
17. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713-22.
18. Steinert HC, Santos Dellea MM, Burger C, Stahel R. Therapy re-sponse evaluation in malignant pleural mesothelioma with inte-grated PET-CT imaging. Lung Cancer. 2005;49 Suppl 1:S33-5.
19. Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587-93.
20. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiau-tomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449-58.
21. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of ma-lignant pleural mesothelioma. Lung Cancer. 2010;67:311-7.
22. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothe-lioma: a phase II study. J Clin Oncol 1999; 17: 25-30.
23. Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomzed doxorubicin, and gemcitabine. A phase II study. J Thorac Oncol 2008 Nov;3(11):1325-31
24. Sugarbaker DJ, Norberto JJ, Swanson SJ. Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:356-60.
25. Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:347-55.
26. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257-60.
27. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lam-mertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82.